Inventiva (NASDAQ:IVA) Stock Price Down 4.9% – Should You Sell?

Inventiva S.A. Sponsored ADR (NASDAQ:IVA)’s stock price was down 4.9% during trading on Monday . The company traded as low as $3.62 and last traded at $3.5950. 70,300 shares changed hands during mid-day trading, a decline of 90% from the average daily volume of 717,108 shares. The stock had previously closed at $3.78.

Analysts Set New Price Targets

Several analysts have recently weighed in on IVA shares. Piper Sandler restated an “overweight” rating on shares of Inventiva in a research report on Wednesday. Guggenheim raised their price target on Inventiva from $11.00 to $14.00 and gave the company a “buy” rating in a research report on Tuesday, September 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Inventiva in a research note on Friday, July 17th. Finally, Cantor Fitzgerald assumed coverage on Inventiva in a research report on Friday, July 17th. They set an “overweight” rating on the stock. Three analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Buy” and an average target price of $15.75.

Inventiva Stock Performance

The business has a 50 day moving average price of $4.52 and a two-hundred day moving average price of $4.85.

Institutional Investors Weigh In On Inventiva

Large investors have recently added to or reduced their stakes in the company. Engineers Gate Manager LP raised its stake in shares of Inventiva by 155.5% during the second quarter. Engineers Gate Manager LP now owns 71,116 shares of the company’s stock valued at $269,000 after acquiring an additional 43,280 shares during the last quarter. Seven Fleet Capital Management LP bought a new stake in shares of Inventiva in the first quarter worth about $1,111,000. Persistent Asset Partners Ltd purchased a new position in Inventiva during the 4th quarter valued at about $603,000. NEXTBio Capital Management LP purchased a new position in Inventiva during the 4th quarter valued at about $6,039,000. Finally, Eventide Asset Management LLC purchased a new stake in Inventiva in the 4th quarter worth approximately $1,155,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Company Profile

Inventiva SA is a clinical-stage biopharmaceutical company headquartered in Daix, France. The company develops small-molecule therapies for metabolic, liver and autoimmune diseases, with a focus on conditions that have limited treatment options.

Inventiva’s lead product candidate is lanifibranor, an oral pan-PPAR agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). The investigational therapy is intended to address liver inflammation and fibrosis associated with the disease and is being evaluated in late-stage clinical development.